Cloned Monkeys: A Gene Technology Breakthrough
The challenges and potential of cloning mammalian animals, including the recent success of cloning a rhesus monkey, are explored in ...
- Latest
- Trending
The challenges and potential of cloning mammalian animals, including the recent success of cloning a rhesus monkey, are explored in ...
RBC Capital upgrades Regeneron to Outperform, raises price target to $1,076 from $884, citing its prolific R&D engine and recent ...
Biotech venture capitalists find hope in recent small M&A deals, signaling stability and growth in the industry. Lack of IPOs ...
REGENXBIO to Present Phase II Trial Results for Experimental AMD Gene Therapy at Hawaiian Eye and Retina Meeting. Promising outcomes ...
Johnson & Johnson's acquisition of Ambrx showcases the power of biotech M&A, rewarding investors with staggering returns and highlighting the ...
Analysis: Global Venture Capital Movement in 2023 reveals a slowdown in VC activity, but the Central Coast shows potential for ...
Johnson & Johnson's $2 billion acquisition of Ambrx Biopharma emphasizes its focus on oncology and targeted cancer treatments. #PharmaNews
San Diego-based CRISPR QC secures Series A funding from Xcellerant Ventures, driving further developments in its CRISPR Analytics Platform.
OnCusp Therapeutics raises $100M in Series A funding to advance its research and development efforts in innovative therapeutics. #biotech #funding
Biotech ETFs offer investors a way to access the potential gains of the biotech industry. From breakthrough medicines to innovative ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.